Managing Cesarean Scars

Cesarean delivery is among the most common surgical procedures worldwide, yet postoperative scarring remains a persistent challenge. Keloid formation represents the most severe and recurrent outcome, extending beyond the incision and carrying long‑term cosmetic and psychosocial impact. Conventional closure techniques do little to address the biologic drivers of abnormal scar formation, leaving obstetricians with limited options to prevent recurrence.

Amniotic membrane (AM) allografts offer a biologically active solution. Evidence from ocular surgery demonstrates AM’s ability to suppress transforming growth factor‑beta (TGF‑β) signaling, inhibit myofibroblast differentiation, and reduce fibrotic scarring. Dermatology and wound care studies further confirm its role in regulating collagen deposition and improving healing outcomes. These findings establish a consistent mechanistic rationale for extending AM use to obstetric surgery, where cesarean incisions are uniquely prone to abnormal scarring due to incision tension, repeat procedures, and patient‑specific predisposition to keloids.

By modulating fibrotic pathways, reducing local inflammation, and balancing extracellular matrix remodeling, AM allografts directly address the biologic conditions that foster keloid scars. For obstetricians, this represents a credible, mechanism‑driven adjunct that integrates seamlessly into existing surgical workflows, supporting regenerative healing and improving maternal recovery while reducing the risk of persistent keloid formation.

Post‑Cesarean Scar Management in Obstetrics

For obstetricians, amniotic membrane allografts represent a credible, mechanism‑driven adjunct to regulate collagen synthesis, suppress TGF‑β signaling, and improve maternal recovery. This biologically active approach reduces the risk of keloid scar development while integrating seamlessly into existing cesarean closure techniques.

Start a Conversation

Clinical Considerations

A: AM provides biologic reinforcement by modulating fibrotic pathways, reducing inflammation, and supporting balanced ECM remodeling. By regulating collagen deposition, AM helps prevent excessive scar tissue and promotes organized healing at the incision site.

A: AM downregulates TGF‑β signaling, limits fibroblast proliferation, and promotes regenerative healing. This biologic control tempers collagen overproduction, steering scar tissue toward a more physiologic, less fibrotic architecture.

A: Yes. AM allografts are regulated under 21 CFR Part 1271, Section 361, for homologous use. In cesarean scar management, this aligns with AM’s natural role in modulating collagen and ECM remodeling during wound healing.

A: Extensive ocular data demonstrates AM’s anti‑fibrotic effects, reinforced by dermatology and wound care studies. These findings highlight AM’s ability to regulate collagen turnover and suppress excessive scar tissue formation, supporting its application in obstetric incisions.

A: Existing wound graft codes (CPT 15275–15276, HCPCS Q4100) and hypertrophic scar diagnoses (ICD‑10 L91.0) provide administrative pathways. These codes support reimbursement for biologic grafts used to regulate collagen deposition and manage cesarean scar outcomes.

1. Tseng, S. C. G., Li, D. Q., & Ma, X. (1999). Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. Journal of Cellular Physiology, 179(3), 325–

2. Eslahi, N., Nejad, Z. M., Rezaei-Tavirani, M., & Akbari, S. (2025). Amniotic membrane transplantation for wound healing, tissue engineering, and regenerative medicine. Stem Cell Reviews and Reports, 21(2), 345–359. https://doi.org/10.1007/s12015-025-10892-x

3. Bhatti, M., Adwan, A., Kamal, R., Singh, K., & Anand, S. (2024). Human amniotic membrane modulates collagen production and enhances wound healing. Scientific Reports, 14(1), 2789. https://doi.org/10.1038/s41598-024-64364-2

4. Davenport, B., Tatro, E., Phillips, H., & Yamin, F. (2019). Amniotic and umbilical cord particulate in the management of keloid and hypertrophic scars. Journal of Wound Care, 28(7), 456–462. https://doi.org/10.12968/jowc.2019.28.7.456A nice paragraph